Clinical studies have demonstrated that combined CDK4/6i and endocrine therapy significantly improves progression-free survival (PFS) and overall survival (OS) compared to endocrine therapy alone in ER+ advanced breast cancer, resulting in the approval of CDK4/6i in the first-line setting combined with an aromatase inhibitor (AI). The gene discussed is CYP19A1; the disease is breast carcinoma.